Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07758231
PHASE1

Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics

Sponsor: University of Wisconsin, Madison

View on ClinicalTrials.gov

Summary

This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.

Key Details

Gender

All

Age Range

21 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

5

Start Date

2026-10

Completion Date

2027-03

Last Updated

2026-08-11

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Acute Ethanol Dose

Time 0, participants will self-administer an oral ethanol beverage (vodka and sugar-free cherry Kool aid) calculated to reach a peak Breath Alcohol Concentration (BrAC) of 0.08 g/dL using the Widmark formula. A total time of 30 minutes will be given for completion of beverage consumption. This will be followed by a breakfast.

Locations (1)

University of Wisconsin

Madison, Wisconsin, United States